Effect of Long-term Postoperative Interferon Therapy on Intrahepatic Recurrence and Survival Rate After Resection of Hepatitis C Virus-related Hepatocellular Carcinoma
Overview
Affiliations
Objective: This study was aimed at evaluating the effects of interferon (IFN)-alpha on survival rate after resection of hepatocellular carcinoma.
Methods: In a randomized, controlled trial by the University Hospital, Medical Center and affiliated hospital in Osaka, Japan, 30 men were after surgery randomly allocated to an IFN-alpha group (15 patients) and to a control group. Patients in the IFN group received 6 MIU of IFN-alpha intramuscularly daily for 2 weeks, then three times a week for 14 weeks, and finally twice a week for 88 weeks. The incidence of recurrence and survival rate were then studied.
Results: The response to IFN was sustained viral response (SVR) in 2 patients, biochemical response (BR) in 6, partial response (PR) in 5, and no response (NR) in 2. In the control, 8 of the 15 patients demonstrated continuous abnormally high levels of ALT. At the end point of the study, intrahepatic recurrence was detected in 9 of the IFN group and in 13 of the control (p = 0.065, log-rank test). The cumulative survival rate was higher in the IFN group than in the controls (p = 0.041).
Conclusion: Postoperative IFN therapy improves the outcome after resection of hepatitis C virus-related hepatocellular carcinoma.
Hepatocellular carcinoma recurrence: Predictors and management.
Abdelhamed W, El-Kassas M Liver Res. 2025; 7(4):321-332.
PMID: 39958776 PMC: 11791921. DOI: 10.1016/j.livres.2023.11.004.
Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition).
Zhou J, Sun H, Wang Z, Cong W, Zeng M, Zhou W Liver Cancer. 2023; 12(5):405-444.
PMID: 37901768 PMC: 10601883. DOI: 10.1159/000530495.
Ye Y, Wang Y, Xu H, Yi F BMC Gastroenterol. 2023; 23(1):320.
PMID: 37730533 PMC: 10510134. DOI: 10.1186/s12876-023-02955-5.
Advances in postoperative adjuvant therapy for primary liver cancer.
Zeng Z, Mo N, Zeng J, Ma F, Jiang Y, Huang H World J Gastrointest Oncol. 2022; 14(9):1604-1621.
PMID: 36187393 PMC: 9516643. DOI: 10.4251/wjgo.v14.i9.1604.
Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q Front Oncol. 2021; 11:709278.
PMID: 34540675 PMC: 8445365. DOI: 10.3389/fonc.2021.709278.